Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies

Antigen-binding fragments of antibodies specific to the tumor-associated ganglioside GD2 are well poised to play a substantial role in modern GD2-targeted cancer therapies, however, rapid elimination from the body and reduced affinity compared to full-length antibodies limit their therapeutic potent...

Full description

Bibliographic Details
Main Authors: Irina V. Kholodenko, Daniel V. Kalinovsky, Elena V. Svirshchevskaya, Igor I. Doronin, Maria V. Konovalova, Alexey V. Kibardin, Tatyana V. Shamanskaya, Sergey S. Larin, Sergey M. Deyev, Roman V. Kholodenko
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/24/21/3835
id doaj-63d260e83a8b4c54842c491d2f1b4b63
record_format Article
spelling doaj-63d260e83a8b4c54842c491d2f1b4b632020-11-25T01:56:34ZengMDPI AGMolecules1420-30492019-10-012421383510.3390/molecules24213835molecules24213835Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific AntibodiesIrina V. Kholodenko0Daniel V. Kalinovsky1Elena V. Svirshchevskaya2Igor I. Doronin3Maria V. Konovalova4Alexey V. Kibardin5Tatyana V. Shamanskaya6Sergey S. Larin7Sergey M. Deyev8Roman V. Kholodenko9Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya St., Moscow 119121, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., Moscow 117997, RussiaD. Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, 1, Samory Mashela St., Moscow 117997, RussiaD. Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, 1, Samory Mashela St., Moscow 117997, RussiaD. Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, 1, Samory Mashela St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Miklukho-Maklaya St., Moscow 117997, RussiaAntigen-binding fragments of antibodies specific to the tumor-associated ganglioside GD2 are well poised to play a substantial role in modern GD2-targeted cancer therapies, however, rapid elimination from the body and reduced affinity compared to full-length antibodies limit their therapeutic potential. In this study, scFv fragments of GD2-specific antibodies 14.18 were produced in a mammalian expression system that specifically bind to ganglioside GD2, followed by site-directed pegylation to generate mono-, di-, and tetra-scFv fragments. Fractionated pegylated dimers and tetramers of scFv fragments showed significant increase of the binding to GD2 which was not accompanied by cross-reactivity with other gangliosides. Pegylated multimeric di-scFvs and tetra-scFvs exhibited cytotoxic effects in GD2-positive tumor cells, while their circulation time in blood significantly increased compared with monomeric antibody fragments. We also demonstrated a more efficient tumor uptake of the multimers in a syngeneic GD2-positive mouse cancer model. The findings of this study provide the rationale for improving therapeutic characteristics of GD2-specific antibody fragments by multimerization and propose a strategy to generate such molecules. On the basis of multimeric antibody fragments, bispecific antibodies and conjugates with cytotoxic drugs or radioactive isotopes may be developed that will possess improved pharmacokinetic and pharmacodynamic properties.https://www.mdpi.com/1420-3049/24/21/3835antibody fragmentspegylationmultimerizationganglioside gd2immunotherapycancerneuroblastoma
collection DOAJ
language English
format Article
sources DOAJ
author Irina V. Kholodenko
Daniel V. Kalinovsky
Elena V. Svirshchevskaya
Igor I. Doronin
Maria V. Konovalova
Alexey V. Kibardin
Tatyana V. Shamanskaya
Sergey S. Larin
Sergey M. Deyev
Roman V. Kholodenko
spellingShingle Irina V. Kholodenko
Daniel V. Kalinovsky
Elena V. Svirshchevskaya
Igor I. Doronin
Maria V. Konovalova
Alexey V. Kibardin
Tatyana V. Shamanskaya
Sergey S. Larin
Sergey M. Deyev
Roman V. Kholodenko
Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
Molecules
antibody fragments
pegylation
multimerization
ganglioside gd2
immunotherapy
cancer
neuroblastoma
author_facet Irina V. Kholodenko
Daniel V. Kalinovsky
Elena V. Svirshchevskaya
Igor I. Doronin
Maria V. Konovalova
Alexey V. Kibardin
Tatyana V. Shamanskaya
Sergey S. Larin
Sergey M. Deyev
Roman V. Kholodenko
author_sort Irina V. Kholodenko
title Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
title_short Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
title_full Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
title_fullStr Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
title_full_unstemmed Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
title_sort multimerization through pegylation improves pharmacokinetic properties of scfv fragments of gd2-specific antibodies
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2019-10-01
description Antigen-binding fragments of antibodies specific to the tumor-associated ganglioside GD2 are well poised to play a substantial role in modern GD2-targeted cancer therapies, however, rapid elimination from the body and reduced affinity compared to full-length antibodies limit their therapeutic potential. In this study, scFv fragments of GD2-specific antibodies 14.18 were produced in a mammalian expression system that specifically bind to ganglioside GD2, followed by site-directed pegylation to generate mono-, di-, and tetra-scFv fragments. Fractionated pegylated dimers and tetramers of scFv fragments showed significant increase of the binding to GD2 which was not accompanied by cross-reactivity with other gangliosides. Pegylated multimeric di-scFvs and tetra-scFvs exhibited cytotoxic effects in GD2-positive tumor cells, while their circulation time in blood significantly increased compared with monomeric antibody fragments. We also demonstrated a more efficient tumor uptake of the multimers in a syngeneic GD2-positive mouse cancer model. The findings of this study provide the rationale for improving therapeutic characteristics of GD2-specific antibody fragments by multimerization and propose a strategy to generate such molecules. On the basis of multimeric antibody fragments, bispecific antibodies and conjugates with cytotoxic drugs or radioactive isotopes may be developed that will possess improved pharmacokinetic and pharmacodynamic properties.
topic antibody fragments
pegylation
multimerization
ganglioside gd2
immunotherapy
cancer
neuroblastoma
url https://www.mdpi.com/1420-3049/24/21/3835
work_keys_str_mv AT irinavkholodenko multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT danielvkalinovsky multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT elenavsvirshchevskaya multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT igoridoronin multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT mariavkonovalova multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT alexeyvkibardin multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT tatyanavshamanskaya multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT sergeyslarin multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT sergeymdeyev multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
AT romanvkholodenko multimerizationthroughpegylationimprovespharmacokineticpropertiesofscfvfragmentsofgd2specificantibodies
_version_ 1724979261397270528